Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy

NCT01673308 is registered in ClinicalTrials.gov with Ulsan University Hospital as lead sponsor.

NCT NCT01673308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01673308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy
Lead sponsor
Ulsan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2012
Completion date
November 30, 2016
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome